ANDAORALTABLET
Approved
Apr 2013
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
VALSARTAN AND HYDROCHLOROTHIAZIDE (valsartan and hydrochlorothiazide) by Viatris (2) is angiotensin 2 receptor antagonists [moa]. Approved for thiazide diuretic [epc]. First approved in 2013.
Drug data last refreshed 21h ago
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Started Oct 2006
601 enrolled
Hypertension
Company
Worked on VALSARTAN AND HYDROCHLOROTHIAZIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.